Literature DB >> 17306257

Abl-SH3 binding protein 2, 3BP2, interacts with CIN85 and HIP-55.

Séverine Le Bras1, Cheol Moon, Isabelle Foucault, Jean-Philippe Breittmayer, Marcel Deckert.   

Abstract

The adapter 3BP2 is involved in leukocyte signaling downstream Src/Syk-kinases coupled immunoreceptors. Here, we show that 3BP2 directly interacts with the endocytic scaffold protein CIN85 and the actin-binding protein HIP-55. 3BP2 co-localized with CIN85 and HIP-55 in T cell rafts and at the T cell/APC synapse, an active zone of receptors and proteins recycling. A binding region of CIN85 SH3 domains on 3BP2 was mapped to a PVPTPR motif in the first proline-rich region of 3BP2, whereas the C-terminal SH3 domain of HIP-55 bound a more distal proline-rich domain of 3BP2. Together, our data suggest an unexpected role of 3BP2 in endocytic and cytoskeletal regulation through its interaction with CIN85 and HIP-55.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17306257     DOI: 10.1016/j.febslet.2007.01.084

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis.

Authors:  Wei Yan; Brooke Bentley; Rong Shao
Journal:  Mol Biol Cell       Date:  2008-03-19       Impact factor: 4.138

2.  CIN85 interacting proteins in B cells-specific role for SHIP-1.

Authors:  Tom Büchse; Nikolaus Horras; Eva Lenfert; Gerald Krystal; Sandra Körbel; Michael Schümann; Eberhard Krause; Stefan Mikkat; Markus Tiedge
Journal:  Mol Cell Proteomics       Date:  2011-07-01       Impact factor: 5.911

Review 3.  RNA therapeutics targeting osteoclast-mediated excessive bone resorption.

Authors:  Yuwei Wang; David W Grainger
Journal:  Adv Drug Deliv Rev       Date:  2011-09-10       Impact factor: 15.470

4.  3BP2 adapter protein is required for receptor activator of NFκB ligand (RANKL)-induced osteoclast differentiation of RAW264.7 cells.

Authors:  Amel GuezGuez; Virginie Prod'homme; Xavier Mouska; Alice Baudot; Claudine Blin-Wakkach; Robert Rottapel; Marcel Deckert
Journal:  J Biol Chem       Date:  2010-05-03       Impact factor: 5.157

5.  SH3BP2 is a critical regulator of macrophage and osteoclast response to M-CSF and RANKL stimulation.

Authors:  Mark S McMahon; Yasuyoshi Ueki
Journal:  HSS J       Date:  2008-10-25

6.  Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.

Authors:  Teruhito Yoshitaka; Shu Ishida; Tomoyuki Mukai; Mizuho Kittaka; Ernst J Reichenberger; Yasuyoshi Ueki
Journal:  J Bone Miner Res       Date:  2014       Impact factor: 6.741

7.  Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities.

Authors:  Matthew D Blunt; Stephen G Ward
Journal:  Front Immunol       Date:  2012-08-02       Impact factor: 7.561

Review 8.  The role of SH3BP2 in the pathophysiology of cherubism.

Authors:  Ernst J Reichenberger; Michael A Levine; Bjorn R Olsen; Maria E Papadaki; Steven A Lietman
Journal:  Orphanet J Rare Dis       Date:  2012-05-24       Impact factor: 4.123

9.  A concerted HIF-1α/MT1-MMP signalling axis regulates the expression of the 3BP2 adaptor protein in hypoxic mesenchymal stromal cells.

Authors:  Sébastien Proulx-Bonneau; Amel Guezguez; Borhane Annabi
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

10.  Pro-oncogenic function of HIP-55/Drebrin-like (DBNL) through Ser269/Thr291-phospho-sensor motifs.

Authors:  Zijian Li; Hae Ryon Park; Zhi Shi; Zenggang Li; Cau Dinh Pham; Yuhong Du; Fadlo R Khuri; Youyi Zhang; Qide Han; Haian Fu
Journal:  Oncotarget       Date:  2014-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.